Breaking News on Pharmaceutical Technology

On your radar > Mergers and acquisitions

News in brief

Lundbeck rumours boost Elan’s share price

30-Mar-2009

Related topics: Mergers and acquisitions, Industry Drivers

Speculation that drugmaker Elan is a takeover target for Denmark’s Lundbeck boosted the Irish drugmakers share price 11 per cent on Friday last week.

While neither firm has commented, articles in both London’s Financial Times and the Irish Independent reported the rumours and said that such a transaction would be in keeping with Elan’s decision to bring in Citigroup to review its strategic options in January.

MF Global’s Manus Cranny told the Independent that: "There may be some substance to [the speculation] as we are seeing corporate bonds ticking slightly higher, which is an indication of some action in the stock."

Other analysts were less convinced and questioned what Lundeck stood to gain from the acquisition.

Follow us on